Some 1,600 doses of the vaccine arrived in Geneva which the WHO, under fire for what has been seen as a lethargic response to the outbreak, hopes can be fast-tracked into "real-world use".
Meanwhile doctors said today two people died in a riot the day before in eastern Sierra Leone, which erupted when health workers tried to take a blood sample from a 90-year-old woman suspected of having Ebola.
Sierra Leone and neighbouring Guinea and Liberia are the epicentre of the Ebola outbreak, the world's worst ever, which has killed more than 4,500 people including a handful outside the region.
Health teams are working desperately to slow the alarming spread of the virus, with experts warning the rate of infections could reach 10,000 a week by early December.
The WHO launched new emergency consultations connecting policymakers and health experts in Geneva and on the ground in west Africa by video and phone.
The third such talks since the WHO declared the outbreak an international crisis in August will likely last two days, with a news conference planned the day after they wrap up.
The WHO is to coordinate trials of the vaccine in Geneva alongside those already under way in Germany, Gabon and Kenya.
The vaccine, developed at the National Microbiology Laboratory in Winnipeg, is one of two experimental Ebola vaccines identified by the WHO as having shown promising results when tested on monkeys.
WHO assistant director general Marie-Paule Kieny said Tuesday the goal was to be able to ship initial supplies to Africa by early 2015, though mass vaccination campaigns are not yet on the cards.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
